ArticleNeuro-oncology advances
[
Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Joint EANM/EANO/RANO/SNMMI practice guideline/procedure standards for diagnostics and therapy (theranostics) of meningiomas using radiolabeled somatostatin receptor ligands: version 1.0.European journal of nuclear medicine and molecular imaging · 2024Guideline
- [Ga68] DOTATATE PET/MRI-guided radiosurgical treatment planning and response assessment in meningiomas.Neuro-oncology · 2024Trial
- Multisession radiosurgery for grade 2 (WHO), high risk meningiomas. A phase II clinical trial.Journal of neuro-oncology · 2022Trial
- Molecular Brain Tumor Imaging Beyond [AJR. American journal of roentgenology · 2026Review
- Multidisciplinary management of meningiomas in the era of precision oncology.Nature reviews. Clinical oncology · 2026Review
- Somatostatin receptor PET in meningioma: diagnosis, therapy, and surveillance.Nuclear medicine communications · 2026Review
- Article
- Combined SSTR2-targeted Analogue withFrontiers in oncology · 2026Article
- Article
- SUV-max ofJournal of neuro-oncology · 2025Article
- SSTR PET/CT for skull base low-grade meningioma: a critical tool for accurate gross tumor volume delineation in radiotherapy?Radiation oncology (London, England) · 2025Article
- The Rationale for Early Adjuvant Radiotherapy After Gross Total Resection of Atypical Meningioma.Neurosurgery · 2025Article
- SSTR2 expression in neoplastic and normal anterior pituitary is impacted by age, sex, and hormonal status.Journal of neuropathology and experimental neurology · 2025Article
- Preoperative PET/MRI and radio-guided surgery using [Cu64]DOTATATE in meningioma: a feasibility study. Illustrative case.Journal of neurosurgery. Case lessons · 2025Article
- Meningioma: Novel Diagnostic and Therapeutic Approaches.Biomedicines · 2025Review
- Meningioma: International Consortium on Meningiomas consensus review on scientific advances and treatment paradigms for clinicians, researchers, and patients.Neuro-oncology · 2024Review
- Article
- The use of PET/MRI in radiotherapy.Insights into imaging · 2024Review
- Somatostatin Receptor-PET/CT/MRI of Head and Neck Neuroendocrine Tumors.AJNR. American journal of neuroradiology · 2023Article
- Peptides for trans-blood-brain barrier delivery.Journal of labelled compounds & radiopharmaceuticals · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMeningiomas express high levels of somatostatin receptor 2 (SSTR2). SSTR2-targeted PET imaging with [
methodsTwenty-nine patients underwent DOTATATE PET/MRI meningioma evaluation in 2019. Eight patients with 9 postoperative meningiomas met RTOG 0539 intermediate-risk criteria (recurrent WHO grade I, 1/9; WHO grade II, 8/9). Target volumes were created using DOTATATE PET/MRI to determine residual disease and received a nominal dose of 35.0 Gy over 5 fractions. For comparison, cases were recontoured and planned with MRI alone per RTOG 0539 guidelines. Mean and maximum equivalent 2 Gy doses were generated for target volumes and organs at risk (OAR) within 1 cm of the PTV and compared using Wilcoxon matched pairs signed rank test.
resultsDOTATATE PET/MRI-guided planning significantly reduced mean PTV (11.12 cm
conclusionIncorporating DOTATATE-PET/MRI for postoperative target delineation in patients with intermediate-risk intracranial meningiomas results in PTV reduction and decreased OAR dose. Our findings warrant larger studies evaluating DOTATATE-PET/MRI in the radiotherapeutic planning of postoperative meningiomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.